Enhanced Lipogenesis Associated With a High-Risk GCKR Variant (rs1260326) is Effectively Suppressed by TLC-2716, a Novel, Liver-Targeted LXR Inverse Agonist in Steatotic Human Liver Organoids (AASLD 2022, Poster #4210)
OrsoBio team members collaborated with Professor Takebe in his pioneering study in Cell on the first use of en masse human liver organoids to define the genetic basis of metabolic liver disease and potential for tailored therapeutic development.
